news
COVID-19 S-Trimer vaccine candidates show promise in early trials
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
List view / Grid view
Proteins
news
COVID-19 vaccines may be less effective for racial minorities, suggest computer scientists
New research suggests that adding extra COVID-19 peptides to a dose of vaccine could increase effectiveness in populations that may not respond robustly to COVID-19 vaccines.
news
FDA grants COVID-19 treatment Fast Track designation
The designation should expedite the development and review of AB201, a recombinant protein therapy being tested in hospitalised COVID-19 patients.
news
FDA approves first treatment for rare paediatric genetic diseases
Zokinvy (lonafarnib) capsules have been approved for the treatment of Hutchinson-Gilford progeria syndrome and certain progeroid laminopathies in patients over one year old.
news
EMA accepts marketing application for Spinal Muscular Atrophy treatment
The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA).
news
COVID-19 rapid antibody tests approved for use in UK
Abingdon Health's COVID-19 rapid antibody test has been registered with the UK's Medicines and Healthcare products Regulatory Agency.
news
Experimental motor neurone disease therapy shows promise
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
news
TXA127 enters multiple Phase II trials in COVID-19 patients
A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
news
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
news
Are thermally stable, ensilicated vaccines the future for childhood inoculations?
Coating the tetanus portion of the DTP vaccine in silica rendered it thermally stable up to 100°C and able to be distributed without refrigeration.
news
Potential cytokine storm treatment identified for severe COVID-19 patients
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
news
Simple but effective: an experimental nanoparticle COVID-19 test
Researchers reveal their experimental test can detect the presence of COVID-19 RNA in a sample in 10 minutes, and in a way that does not require trained personnel to interpret.
news
CDMO delivers 4,000 doses of COVID-19 vaccine candidate for Phase II/III trial
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
news
COVID-19 vaccine induces immune response in Phase I trial
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
news
Two malaria vaccine candidates show signs of efficacy
Clinical trials testing potential malaria vaccines report the vaccines were well tolerated and demonstrated some efficacy, delaying Plasmodium falciparum infection.
